| アブストラクト | Kidney EGFR expression together with reported cases of glomerular diseases in the context of anti-EGFR drug administration raise concerns about the renal safety profile of these drugs. This issue is addressed in a case/non-case study carried out on VigiBase((R)), the WHO global database of individual case safety reports (ICRS). Disproportionality analysis of renal adverse effects related to the selected anti-EGFR drugs, erlotinib, gefitinib, afatinib, osimertinib, cetuximab and panitumumab, was assessed using the reporting odds ratio (ROR). Nine hundred and eighty-nine ICRSs were included. A signal of disproportionate reporting (SDR) was found for afatinib (ROR = 2.70; 95% CI [2.22-3.29]) and erlotinib (ROR = 1.73; 95% CI [1.46-2.04]) with acute kidney injury, and for afatinib (ROR = 2.41; 95% CI [1.78-3.27]), cetuximab (ROR = 1.42; 95% CI [1.14-1.78]) and erlotinib (ROR = 2.23; 95% CI [1.80-2.77]) with renal failure. The preferred term "diarrhoea" was frequently reported in the included cases. An SDR was found for erlotinib with haemolytic and uremic syndrome (ROR = 4.01; 95% CI [1.80-8.94]) and thrombotic microangiopathy (ROR = 4.94; 95% CI [2.80-8.72]). No SDR was seen for glomerular or tubule-interstitial diseases. This study showed that the anti-EGFR drug renal toxicity is mainly related to renal failure in the context of digestive toxicity. |
|---|
| ジャーナル名 | Cancers |
|---|
| Pubmed追加日 | 2021/12/11 |
|---|
| 投稿者 | Crosnier, Alexandre; Abbara, Chadi; Cellier, Morgane; Lagarce, Laurence; Babin, Marina; Bourneau-Martin, Delphine; Briet, Marie |
|---|
| 組織名 | Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital;of Angers, 4 Rue Larrey, 49100 Angers, France.;Departement de Medecine, Faculte de Medecine d'Angers, Universite d'Angers, 49035;Angers, France.;Research Institute MitoVasc, UMR CNRS 6214 INSERM 1083, University of Angers,;49100 Angers, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34885014/ |
|---|
